Related Experiment Video
Updated: Jul 13, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression
Nienke M E Scheltens1, Betty M Tijms1, Martijn W Heymans2
1Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Journal of Alzheimer'S Disease : JAD
|August 15, 2018
Summary
Alzheimer's disease (AD) subtypes show different progression rates. Non-memory impairment subtypes experience faster cognitive decline and increased mortality risk compared to memory impairment subtypes.
Area of Science:
- Neurology
- Neuroscience
- Gerontology
Background:
- Alzheimer's disease (AD) is a complex neurodegenerative disorder with varied clinical presentations.
- Understanding AD heterogeneity is crucial for predicting disease trajectory and patient outcomes.
Purpose of the Study:
- To investigate if distinct cognitive subtypes of AD are associated with differing rates of disease progression.
- To analyze the impact of cognitive subtypes on mortality risk in AD patients.
Main Methods:
- Utilized data from 1,066 probable AD patients across multiple cohorts.
- Clustered patients into memory-predominant and non-memory-predominant subtypes based on neuropsychological testing.
- Employed linear mixed models and Cox proportional hazard analyses to assess disease progression (MMSE, CDR-SB) and mortality risk.
Main Results:
- Non-memory AD subtypes exhibited significantly faster annual decline in Mini-Mental State Examination (MMSE) scores compared to memory subtypes.
- Non-memory subtypes showed a steeper increase in Clinical Dementia Rating scale sum of boxes (CDR-SB) scores, indicating faster functional decline.
- The non-memory subtype was associated with a trend towards increased mortality risk (HR=1.36, p=0.05).
Conclusions:
- Cognitive subtypes in Alzheimer's disease significantly influence disease progression.
- Patients with predominant non-memory impairment face a more rapid decline and a higher risk of mortality.
- These findings highlight the importance of cognitive profiling for personalized AD management.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...